Maternal and neonatal elimination of amobarbital after treatment of the mother with barbiturates during late pregnancy

Clin Pharmacol Ther. 1976 Mar;19(3):271-5. doi: 10.1002/cpt1976193271.

Abstract

Plasma half-lives of amobarbital were determined in newborn children of 10 mothers who had been treated with barbiturates for hypertension in pregnancy for 6 to 42 days prior to delivery. Five mothers had received amobarbital, 200 mg daily, and 5, phenobarbital, 60 to 180 mg daily. Half-lives in 7 of the babies ranged from 16.6 to 49.4 hr, comparable to those previously reported in babies of mothers who had received only a single dose of amobarbital. Thus there was no evidence of induction of amobarbital hydroxylation in these children. Two babies who had a greater than normal rise in serum bilirubin had longer half-lives (86.1 and 117.7 hr). In 1 baby whose mother had membranous glomerulonephritis, plasma amobarbital concentration did not significantly change over the period of the study.

MeSH terms

  • Adult
  • Amobarbital / metabolism*
  • Amobarbital / pharmacology
  • Amobarbital / therapeutic use
  • Barbiturates / pharmacology*
  • Female
  • Half-Life
  • Humans
  • Hypertension / drug therapy
  • Infant, Newborn*
  • Kinetics
  • Male
  • Maternal-Fetal Exchange*
  • Phenobarbital / pharmacology
  • Phenobarbital / therapeutic use
  • Pregnancy
  • Pregnancy Complications, Cardiovascular / drug therapy

Substances

  • Barbiturates
  • Amobarbital
  • Phenobarbital